Hospitals and major drugmakers are battling over the financial impact of a government pilot program that could shake up how medicines are steeply discounted for low-income and uninsured patients.

The nonpartisan scorekeeper’s new report reinforces longstanding concerns about the 340B drug discount program, including ...

A bipartisan group of lawmakers has sent a letter to the Department of Health and Human Services, asking the agency to cancel ...

One of the world’s biggest drug makers is suing the country’s smallest state. The argument is over a federal drug discount program ...

A bipartisan group of 163 lawmakers is urging the Department of Health and Human Services (HHS) to cancel an upcoming pilot ...

The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ongoing scrutiny and congressional, judicial, and industry pressures.

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The American Hospital Association is calling on federal regulators to launch an antitrust investigation into its claims of drug manufacturers’ actions regarding 340B rebate models. In a letter sent to ...

Congress is considering a new bill that, in theory, would boost low-income patients’ - especially Latinos’ - access to ...

HIV remains a persistent public health challenge in the United States. While infection rates have steadily declined over the past decade, access to proven prevention strategies—especially pre-exposure ...

Commercial: Is the 340B Drug Pricing Program the Next 'Too Big to Fail'? WASHINGTON, Aug. 19, 2025 /PRNewswire/ -- ADAP Advocacy today, as part of its 340B Project, aired its latest commercial calling ...

New York hospitals that participate in 340B should be required to publicly report how much revenue they generate from the program.